Clinuvel Pharmaceuticals Limited (ASX:CUV)

Clinuvel Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	83.97	81.22	72.18	60	42.6	26.31
Other Revenue	7.06	6.96	6.14	5.72	5.72	6.26
Revenue	91.02	88.18	78.32	65.72	48.32	32.57
Revenue Growth (YoY)	11.34%	12.58%	19.17%	36.02%	48.37%	4.89%
Cost of Revenue	8.35	7.73	7.52	9.25	4.17	7.3
Gross Profit	82.68	80.45	70.8	56.47	44.15	25.26
Selling, General & Admin	25.21	22.84	15.65	13.03	11.57	12.23
Research & Development	4.44	2.35	1.27	1.23	0.55	0.34
Other Operating Expenses	-0.56	-0.56	-0.02	-0.22	-	-
Operating Expenses	31.73	31.88	26.67	20.92	15.58	13.01
Operating Income	50.94	48.57	44.13	35.55	28.57	12.25
Interest Expense	-4.41	-4.45	-3.19	-2.27	-1.62	-2.05
Interest & Investment Income	8.28	7.32	3.91	0.44	-	0.56
Currency Exchange Gain (Loss)	2.99	-0.76	0.74	0.6	-1.37	0.65
Other Non Operating Income (Expenses)	-	-	-	-	-	0
EBT Excluding Unusual Items	57.81	50.68	45.58	34.32	25.58	11.41
Other Unusual Items	-	-	-	-	0.13	0.13
Pretax Income	57.81	50.68	45.58	34.32	25.71	11.54
Income Tax Expense	19.03	15.04	14.97	13.44	0.98	-3.51
Earnings From Continuing Operations	38.78	35.64	30.6	20.88	24.73	15.05
Net Income	38.78	35.64	30.6	20.88	24.73	15.05
Net Income to Common	38.78	35.64	30.6	20.88	24.73	15.05
Net Income Growth	28.60%	16.44%	46.58%	-15.57%	64.29%	-17.00%
Shares Outstanding (Basic)	50	50	49	49	49	49
Shares Outstanding (Diluted)	50	51	52	52	51	50
Shares Change (YoY)	-2.63%	-1.52%	0.08%	1.26%	1.33%	1.73%
EPS (Basic)	0.77	0.72	0.62	0.42	0.50	0.31
EPS (Diluted)	0.77	0.70	0.59	0.40	0.48	0.30
EPS Growth	31.92%	18.11%	46.65%	-16.74%	62.42%	-18.58%
Free Cash Flow	23.49	31.48	35.88	39.44	18.41	13.3
Free Cash Flow Per Share	0.47	0.62	0.69	0.76	0.36	0.26
Dividend Per Share	0.050	0.050	0.050	0.040	0.025	0.025
Dividend Growth	-	-	25.00%	60.00%	-	-
Gross Margin	90.83%	91.23%	90.40%	85.92%	91.36%	77.58%
Operating Margin	55.97%	55.08%	56.34%	54.09%	59.12%	37.62%
Profit Margin	42.60%	40.41%	39.08%	31.77%	51.18%	46.22%
Free Cash Flow Margin	25.81%	35.70%	45.82%	60.01%	38.10%	40.84%
EBITDA	51.73	49.32	44.52	35.97	29.07	12.42
EBITDA Margin	56.83%	55.93%	56.85%	54.74%	60.16%	38.12%
D&A For EBITDA	0.79	0.75	0.4	0.43	0.5	0.16
EBIT	50.94	48.57	44.13	35.55	28.57	12.25
EBIT Margin	55.97%	55.08%	56.34%	54.09%	59.12%	37.62%
Effective Tax Rate	32.92%	29.68%	32.85%	39.17%	3.83%	-
Revenue as Reported	102.86	95.31	82.99	-	-	-

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.